Phase 3 N=241 Improving Function in Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Targeted Vision Function (TVF) — 2.18; 2.14 units on a scale — p=.47
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 A Multi-Center Study of Reading Rehabilitation in Macular Disease
Age Related Maculopathy · Retinal Degeneration
Primary: Sentence Reading — 58.9; 50.5; 86.2; 49.1 Words per Minute (wpm)
Phase 2 N=20 Lucentis in Advanced Macular Degeneration
Macular Degeneration
Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02
N/A N=26 Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05
Phase 3 N=188 Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Age-related Macular Degeneration · Depression
Primary: Depression — 11; 18; 5; 11 participants — p=.067
N/A N=27 Micropulse for Suppression of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76
Phase 3 N=702 Treatment for CI-DME in Eyes With Very Good VA Study
Diabetic Macular Edema
Primary: Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline — 33; 36; 39 Eyes
N/A N=33 Translation of Eye Movement Reading Training to Clinical Practice
Macular Disease
Primary: Change in Reading Performance and Accuracy Using MNREAD. — 22.59; 24.68 Words Per Minuted (WPM) — p=0.876
Phase 3 N=1,009 Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 — 7.03; 6.06; 5.89 scores on a scale — p=0.0009
N/A N=33 Efficacy of Acupuncture in Macular Diseases
Age-related Macular Degeneration · Stargardt Disease · Macular Dystrophy
Primary: Change on Visual Acuity (VA) of the Treated Eyes From Baseline to the End of the Study — 36; 16; 4 Eyes
Phase 4 N=44 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
N/A N=4 Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas
Scotoma, Central · Central Visual Impairment
Primary: Improvement in Eye-hand Coordination — 42.8; 45.4; 30.4; 71.0 Percentage
Phase 3 N=406 Intravitreal Aflibercept Injection in Vision Impairment Due to DME
Diabetes Mellitus · Macular Edema
Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
N/A N=68,563 Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
Geographic Atrophy
Primary: Change in Visual Acuity (VA) in Participant's Study Eye — -2.8; -5.9; -8.6; -10.3 Letters read
Phase 2 N=40 Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Macular Edema · Retinal Vein Occlusion
Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters
Phase 3 N=295 Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants
Early Phase 1 N=8 Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
AMD
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
N/A N=22 Optical Head-Mounted Display Technology for Low Vision Rehabilitation
Retinal Dystrophies · Healthy
Primary: Change in the Planimetric Area of Goldmann Visual Field With the Use of Head-mounted Display Technology Compared to Baseline (Measured in Degrees Squared) — 563.08…
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 2 N=53 A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Primary: BCVA Response Defined as an Increased in 10 Letters at 1 Year Post-implant — 3; 3; 1; 9 eyes
N/A N=900 Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
Diabetic Retinopathy · Diabetic Eye Problems · Diabetic Macular Edema
Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives
Early Phase 1 N=9 Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Reticular Pseudodrusen (RPD) · Age-Related Macular Degeneration
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
Phase 2 N=5 Sirolimus to Treat Diabetic Macular Edema
Diabetic Retinopathy
Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters
Phase 3 N=399 Anti-VEGF Treatment for Prevention of PDR/DME
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Development of PDR and/or DME (Whichever Came First) — 27; 75 Eyes
N/A N=19 Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration
Macular Degeneration · Retinal Drusen
Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3
Phase 3 N=731 Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
Diabetic Retinopathy
Primary: Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME) — 1.72; 1.69 months per participant — p=0.969
Phase 2 N=56 Ranibizumab and Bevacizumab for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study) — 5.3; 6.6…
Phase 3 N=178 To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
Macular Edema (ME)
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye — 5.7; 2.9 letters — p=0.0111
Phase 2 N=323 Low Vision Intervention Trial II (LOVIT II)
Central Vision Loss From Macular Diseases
Primary: Comparison of Changes in Visual Reading Ability From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire — 1.29; 0.95…